Entropy Technologies LP Makes New $1.66 Million Investment in Astrazeneca Plc $AZN

Entropy Technologies LP acquired a new position in shares of Astrazeneca Plc (NYSE:AZN) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 9,439 shares of the company’s stock, valued at approximately $1,657,000.

Other large investors also recently bought and sold shares of the company. Triumph Capital Management purchased a new position in Astrazeneca during the 3rd quarter worth $25,000. Bangor Savings Bank grew its stake in shares of Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares during the period. Eagle Bay Advisors LLC acquired a new position in shares of Astrazeneca during the 4th quarter worth $30,000. YANKCOM Partnership acquired a new position in shares of Astrazeneca during the 4th quarter worth $31,000. Finally, TFC Financial Management Inc. grew its stake in shares of Astrazeneca by 3,350.0% during the 4th quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock worth $32,000 after purchasing an additional 335 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

AZN has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Finally, Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Price Performance

Shares of NYSE AZN opened at $177.36 on Tuesday. The stock has a market cap of $275.07 billion, a price-to-earnings ratio of 26.63, a PEG ratio of 1.55 and a beta of 0.25. Astrazeneca Plc has a 52 week low of $137.23 and a 52 week high of $212.71. The company’s 50-day moving average price is $188.74 and its 200 day moving average price is $186.10. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The firm had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, research analysts forecast that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.